Search
Atrasentan
go.drugbank.com/drugs/DB06199ApprovedInvestigationalAtrasentan is a novel, selective endothelin A receptor antagonist (SERA). In April 2025, atrasentan was granted accelerated approval by the FDA for the reduction of proteinuria in patients with primary IgA nephropathy, becoming the first...
Categories: Cytochrome P-450 CYP2B6 Inducers, P-glycoprotein inhibitorsAlogliptin
go.drugbank.com/drugs/DB06203ApprovedInvestigationalAlogliptin is a selective, orally-bioavailable inhibitor of enzymatic activity of dipeptidyl peptidase-4 (DPP-4). Chemically, alogliptin is prepared as a benzoate salt and exists predominantly as the R-enantiomer (>99%). It undergoes ...
Mixtures: INCRESINA PCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 SubstratesTapentadol
go.drugbank.com/drugs/DB06204ApprovedInvestigationalTapentadol is a centrally-acting synthetic analgesic with a dual mechanism of action. It is a mu-opioid receptor agonist that also inhibits norepinephrine reuptake. Tapentadol was first approved by the FDA on November 20, 2008. The exten...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C9 SubstratesSilodosin
go.drugbank.com/drugs/DB06207ApprovedInvestigationalSilodosin is a selective antagonist of alpha(α)-1 adrenergic receptors that binds to the α1A subtype with the highest affinity. α1-adrenergic receptors regulate smooth muscle tone in the bladder neck, prostate, and prostatic urethra: the...
Categories: Cytochrome P-450 Substrates, P-glycoprotein substratesPrasugrel
go.drugbank.com/drugs/DB06209ApprovedInvestigationalPrasugrel, a thienopyridine derivative, is a platelet activation and aggregation inhibitor structurally and pharmacologically related to clopidogrel and ticlopidine. Similar to clopidogrel, prasugrel is a prodrug that requires enzymatic ...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2B6 SubstratesEltrombopag
go.drugbank.com/drugs/DB06210ApprovedInvestigationalEltrombopag is used to treat low blood platelet counts in adults with chronic immune (idiopathic) thrombocytopenia (ITP), when certain other medicines, or surgery to remove the spleen, have not worked well enough. ITP is a condition that...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesVernakalant
go.drugbank.com/drugs/DB06217ApprovedInvestigationalVernakalant was developed by Cardiome Pharma as as an antiarrhythmic drug intended for rapid conversion of atrial fibrillation to sinus rhythm. It acts as an atypical class III antiarrhythmic drug that potentiates its effect in higher he...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 InhibitorsLacosamide
go.drugbank.com/drugs/DB06218ApprovedInvestigationalLacosamide is an antiepileptic drug used to treat seizures. As a chiral functionalized amino acid, it works by blocking slowly inactivating components of voltage-gated sodium currents. Lacosamide exhibits a stereoselective mode of intera...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesNalmefene
go.drugbank.com/drugs/DB06230ApprovedInvestigationalWithdrawnNalmefene, a 6-methylene analogue of naltrexone, is an opioid receptor antagonist. It acts as an antagonist at the mu (μ)-opioid and delta (δ)-opioid receptors and a partial agonist at the kappa (κ)-opioid receptor. In Europe, nalmefene ...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesRidaforolimus
go.drugbank.com/drugs/DB06233InvestigationalCategories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors